Folia Health has launched an at-home study for individuals with C3 glomerulopathy (C3G) in partnership with Novartis. The study...

Albatroz Therapeutics announced research published in •Nature Communications• demonstrating a novel therapeutic approach for arthritis using anti-Calnexin antibodies. The...

Clearmind Medicine Inc. has launched a Phase I/IIa clinical trial for its novel Alcohol Use Disorder (AUD) treatment, CMND-100,...

Theriva Biologics announced the presentation of interim safety and pharmacokinetic data from its ongoing Phase 1b/2a clinical trial of...

Unicycive Therapeutics announced positive patient-reported outcomes from a Phase 2 trial of its oxylanthanum carbonate (OLC) drug for hyperphosphatemia...

BriaPro Therapeutics, a majority-owned subsidiary of BriaCell Therapeutics, is developing novel, high-affinity antibodies targeting B7-H3, a molecule implicated in...

Microbot Medical presented positive data from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System at the Society...

Grace Therapeutics, a late-stage biopharmaceutical company, announced positive feedback from the FDA regarding its planned New Drug Application (NDA)...

Context Therapeutics has dosed the first patient in a Phase 1 clinical trial for CT-95, a bispecific antibody targeting...

Atea Pharmaceuticals has initiated its Phase 3 C-BEYOND trial, evaluating the bemnifosbuvir and ruzasvir regimen for chronic hepatitis C...